eribulin (halaven) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
ERIBULIN MESYLATE (HALAVEN®) is a microtubule dynamics inhibitor. It is a synthetic analog of halichondrin B, a product isolated from the marine sponge Halichondria okadai. ERIBULIN MESYLATE (HALAVEN®) inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. It exerts its effects via a tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after the prolonged mitotic blockage. ERIBULIN MESYLATE (HALAVEN®) is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. It is also indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.   NCATS

Chemistry

  • SMILES: C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C
  • InChIKey: UFNVPOGXISZXJD-JBQZKEIOSA-N
  • Mol. Mass: 729.91
  • ALogP: 3.44
  • ChEMBL Molecules:
    eribulin  
    eribulin mesylate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$176.7684

United States

$447.7800 - $559.2450
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9h,15h-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4h)-one | b 1793 | b-1793 | b 1939 | b-1939 | e7389 | e 7389 | e-7389 | er086526 | er 086526 | er-086526 | er-86526 | eribulin | eribulin (as mesylate) | eribulin mesilate | eribulin mesylate | eribulin monomethanesulfonate | halaven | nsc707389 | nsc 707389 | nsc-707389

Organizations (131)

Research & Development (131)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (45)

Approved Indications (1)


 

Breast Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (45)


 

Adenocarcinoma (Phase 2)

Brain Neoplasms (Phase 3)

BRCA1 Protein (Phase 2)

Breast Neoplasms ()

Breast Neoplasms, Male (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Endometrial Neoplasms (Phase 1)

Fallopian Tube Neoplasms (Phase 2)

Hamartoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Hemangioendothelioma, Epithelioid (Phase 2)

Hemangiosarcoma (Phase 2)

Infertility, Male (Phase 1)

Inflammatory Breast Neoplasms (Phase 2)

Leiomyosarcoma (Phase 2)

Liposarcoma (Phase 2)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 1)

Melanoma (Phase 1)

Meningeal Carcinomatosis (Phase 3)

Mutation (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms ()

Osteosarcoma (Phase 2)

Ovarian Diseases (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pediatrics (Phase 1)

Peripheral Nerve Injuries (Phase 1/Phase 2)

Postmenopause (Phase 2)

Prostatic Neoplasms (Phase 2)

Rhabdomyosarcoma (Phase 2)

Salivary Gland Neoplasms (Phase 2)

Sarcoma (Phase 3)

Sarcoma, Ewing (Phase 2)

Solitary Fibrous Tumors (Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Ureteral Neoplasms (Phase 3)

Urethral Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 2)

Uterine Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 172
  • # of Trial Organizations: 131

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue